Impact of COVID‐19 pandemic on lung cancer treatment scheduling
The current coronavirus disease 2019 (COVID‐19) pandemic is associated with a heavy burden on the mental and physical health of patients, regional healthcare resources, and global economic activity. Many patients with lung cancer are thought to be affected by this situation. Therefore, in this study...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-10-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13615 |
| _version_ | 1818934106349633536 |
|---|---|
| author | Kohei Fujita Takanori Ito Zentaro Saito Osamu Kanai Koichi Nakatani Tadashi Mio |
| author_facet | Kohei Fujita Takanori Ito Zentaro Saito Osamu Kanai Koichi Nakatani Tadashi Mio |
| author_sort | Kohei Fujita |
| collection | DOAJ |
| description | The current coronavirus disease 2019 (COVID‐19) pandemic is associated with a heavy burden on the mental and physical health of patients, regional healthcare resources, and global economic activity. Many patients with lung cancer are thought to be affected by this situation. Therefore, in this study, we aimed to evaluate the impact of COVID‐19 pandemic on lung cancer treatment scheduling. We retrospectively reviewed the medical records of lung cancer patients who were undergoing anticancer treatment at the National Hospital Organization Kyoto Medical Center (600 beds) in Kyoto, Japan, between 1 March 2020 and 31 May 2020. After the medical records were reviewed, the patients were assigned to one of two groups, depending on whether their lung cancer treatment schedule was delayed. We assessed the characteristics, types of histopathology and treatment, and the reason for the delay. A total 15 (9.1%) patients experienced a delay in lung cancer treatment during the COVID‐19 pandemic. Patients with a treatment delay received significantly more immune checkpoint inhibitor (ICI) monotherapy than patients without a treatment delay (P = 0.0057). On the contrary, no patients receiving molecular targeted agents experienced a treatment delay during the COVID‐19 pandemic period (P = 0.0027). The treatments of most of the patients were delayed at their request. We determined that 9.1% lung cancer patients suffered anxiety and requested a treatment delay during the COVID‐19 pandemic. Oncologists should bear in mind that patients with cancer have more anxiety than expected under unprecedented circumstances such as the COVID‐19 pandemic. |
| first_indexed | 2024-12-20T04:59:00Z |
| format | Article |
| id | doaj.art-3392b9dd13e847fe9a4eb598c9a0d305 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-20T04:59:00Z |
| publishDate | 2020-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-3392b9dd13e847fe9a4eb598c9a0d3052022-12-21T19:52:36ZengWileyThoracic Cancer1759-77061759-77142020-10-0111102983298610.1111/1759-7714.13615Impact of COVID‐19 pandemic on lung cancer treatment schedulingKohei Fujita0Takanori Ito1Zentaro Saito2Osamu Kanai3Koichi Nakatani4Tadashi Mio5Division of Respiratory Medicine, Center for Respiratory Diseases National Hospital Organization Kyoto Medical Center Kyoto JapanDivision of Respiratory Medicine, Center for Respiratory Diseases National Hospital Organization Kyoto Medical Center Kyoto JapanDivision of Respiratory Medicine, Center for Respiratory Diseases National Hospital Organization Kyoto Medical Center Kyoto JapanDivision of Respiratory Medicine, Center for Respiratory Diseases National Hospital Organization Kyoto Medical Center Kyoto JapanDivision of Respiratory Medicine, Center for Respiratory Diseases National Hospital Organization Kyoto Medical Center Kyoto JapanDivision of Respiratory Medicine, Center for Respiratory Diseases National Hospital Organization Kyoto Medical Center Kyoto JapanThe current coronavirus disease 2019 (COVID‐19) pandemic is associated with a heavy burden on the mental and physical health of patients, regional healthcare resources, and global economic activity. Many patients with lung cancer are thought to be affected by this situation. Therefore, in this study, we aimed to evaluate the impact of COVID‐19 pandemic on lung cancer treatment scheduling. We retrospectively reviewed the medical records of lung cancer patients who were undergoing anticancer treatment at the National Hospital Organization Kyoto Medical Center (600 beds) in Kyoto, Japan, between 1 March 2020 and 31 May 2020. After the medical records were reviewed, the patients were assigned to one of two groups, depending on whether their lung cancer treatment schedule was delayed. We assessed the characteristics, types of histopathology and treatment, and the reason for the delay. A total 15 (9.1%) patients experienced a delay in lung cancer treatment during the COVID‐19 pandemic. Patients with a treatment delay received significantly more immune checkpoint inhibitor (ICI) monotherapy than patients without a treatment delay (P = 0.0057). On the contrary, no patients receiving molecular targeted agents experienced a treatment delay during the COVID‐19 pandemic period (P = 0.0027). The treatments of most of the patients were delayed at their request. We determined that 9.1% lung cancer patients suffered anxiety and requested a treatment delay during the COVID‐19 pandemic. Oncologists should bear in mind that patients with cancer have more anxiety than expected under unprecedented circumstances such as the COVID‐19 pandemic.https://doi.org/10.1111/1759-7714.13615COVID‐19lung cancerpandemicSARS‐CoV‐2treatment delay |
| spellingShingle | Kohei Fujita Takanori Ito Zentaro Saito Osamu Kanai Koichi Nakatani Tadashi Mio Impact of COVID‐19 pandemic on lung cancer treatment scheduling Thoracic Cancer COVID‐19 lung cancer pandemic SARS‐CoV‐2 treatment delay |
| title | Impact of COVID‐19 pandemic on lung cancer treatment scheduling |
| title_full | Impact of COVID‐19 pandemic on lung cancer treatment scheduling |
| title_fullStr | Impact of COVID‐19 pandemic on lung cancer treatment scheduling |
| title_full_unstemmed | Impact of COVID‐19 pandemic on lung cancer treatment scheduling |
| title_short | Impact of COVID‐19 pandemic on lung cancer treatment scheduling |
| title_sort | impact of covid 19 pandemic on lung cancer treatment scheduling |
| topic | COVID‐19 lung cancer pandemic SARS‐CoV‐2 treatment delay |
| url | https://doi.org/10.1111/1759-7714.13615 |
| work_keys_str_mv | AT koheifujita impactofcovid19pandemiconlungcancertreatmentscheduling AT takanoriito impactofcovid19pandemiconlungcancertreatmentscheduling AT zentarosaito impactofcovid19pandemiconlungcancertreatmentscheduling AT osamukanai impactofcovid19pandemiconlungcancertreatmentscheduling AT koichinakatani impactofcovid19pandemiconlungcancertreatmentscheduling AT tadashimio impactofcovid19pandemiconlungcancertreatmentscheduling |